1. | streetstock43rac | |
2. | lea4582et | |
3. | zpc9909 | |
4. | mmagwitz | |
5. | imaflygirlpilot |
1. | streetstock43rac | |
2. | lea4582et | |
3. | zpc9909 | |
4. | mmagwitz | |
5. | imaflygirlpilot |
1. | lea4582et 01/18/2018 Pricing of $475 Million Public Offering |
2. | streetstock43rac 01/08/2018 a little news - Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value |
3. | zpc9909 02/14/2018 Misses EPS loss estimates by $0.15 and misses on revenues |
4. | lea4582et 01/17/2018 Agios Announces Proposed Offering of Common Stock - up to $400 million |
5. | lea4582et 06/03/2018 Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent |
6. | streetstock43rac 04/11/2018 Credit Suisse sets PT at $95 |
7. | mmagwitz 01/18/2018 Stock rebounded and did better than I thought, down only 3% |
8. | streetstock43rac 05/17/2018 Company will present new clinical data from its IDH Programs at ASCO |
9. | zpc9909 02/14/2018 Agios Reports Fourth Quarter and Full Year 2017 Financial Results |
10. | imaflygirlpilot 02/15/2018 FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation |